May 17, 2026 by Anders BylundIs Micron the Next Nvidia?Micron is having an Nvidia moment. That doesn't make it the next Nvidia.
May 17, 2026 by Geoffrey SeilerThe AI Stock With a 10-Year Head Start That Wall Street Still Hasn't Fully Priced InAlphabet has a huge advantage with its TPUs, which it developed more than a decade ago.
May 17, 2026 by Matt DiLalloAres Capital's 10% Yield Just Survived a Tough Quarter. Is the BDC Still a Buy?Ares Capital isn't worried about last quarter's challenges.
May 17, 2026 by Jonathan PoncianoKBR Stock Has Fallen 45% This Past Year, but One Investor Just Disclosed a New $24 Million BetThis engineering and technology firm delivers mission-critical solutions to government and industrial clients worldwide.
May 17, 2026 by Anders BylundIs Micron the Next Nvidia?Micron is having an Nvidia moment. That doesn't make it the next Nvidia.
May 17, 2026 by Seena HassounaServisFirst Gets Axed by Champlain — a Minor Position in a Major DrawdownServisFirst Bancshares delivers commercial and retail banking services across the Southeast with a relationship-driven approach.
May 17, 2026 by Seena HassounaCrafting title options within editorial guidelines An ETF Shop Just Made a Beaten-Down Medtech Its Top HoldingArtivion delivers advanced cardiovascular and vascular solutions to healthcare providers worldwide through its proprietary medical devices.
May 17, 2026 by Jonathan PoncianoBoxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next PhaseCorvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.
May 17, 2026 by Keithen DruryWhat Is the Cheapest "Magnificent Seven" Stock?There are two companies investors should consider for bargain values.
May 17, 2026 by Jonathan PoncianoWhy One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping RallyThis clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.
May 17, 2026 by Jonathan PoncianoVir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million SharesVir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.
May 17, 2026 by Seena HassounaA China Tech Fund Opens a Biotech Position — Here's What That Actually SignalsLegend Biotech develops cell therapies for cancer, with a pipeline spanning hematologic malignancies and solid tumors.
May 17, 2026 by Beth McKennaNvidia Stock Is Poised to Rocket From the Booming Space EconomyNvidia dominates artificial intelligence (AI) on Earth – and it should do the same for AI in space.
May 17, 2026 by Seena HassounaWith YMM Down 29%, First Beijing Bought 13 Million More SharesFull Truck Alliance is a top digital freight platform in China, connecting shippers and truckers through tech-enabled logistics services.
May 17, 2026 by Seena HassounaGDS Was Already Up 47% — Pinpoint Tripled Its Stake AnywayGDS Holdings develops and operates data centers in China, serving major cloud, internet, and financial sector clients.
May 17, 2026 by Geoffrey SeilerThe AI Stock With a 10-Year Head Start That Wall Street Still Hasn't Fully Priced InAlphabet has a huge advantage with its TPUs, which it developed more than a decade ago.
May 17, 2026 by Keith NoonanWhy Plug Power Stock Skyrocketed This WeekPlug Power served up some promising news for investors this week.
May 17, 2026 by Marc GubertiSnapchat: Don't Rush to Buy This Social Media StockSnap is unprofitable after almost 15 years and doesn't have the revenue growth rates of an exciting start-up.
May 17, 2026 by Kailey Hagen, CFPThink Delaying Social Security Is Risky? The Truth About Timing Your Benefits.There's no cut-and-dried answer about the best time to sign up for benefits.
May 17, 2026 by Seena HassounaM&G Shaved 2.4% of Methanex After a Near-DoublingMethanex supplies methanol worldwide, using integrated operations and its own fleet to serve industrial clients across major global markets.
May 17, 2026 by Jonathan PoncianoMaze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in SharesMaze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases.
May 17, 2026 by Jonathan PoncianoTyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More SharesTyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.
May 17, 2026 by Jonathan PoncianoThis Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 MillionViridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a primary focus on thyroid eye disease.
